An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...
Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing ...
Medpage Today on MSN2mon
Anti-TIGIT Shows Promise in Unresectable Liver CancerAddition of the anti-TIGIT monoclonal antibody tiragolumab to standard ... the 18 patients who received the standard regimen ...
Tecentriq is a monoclonal antibody designed to bind with PD-L1 ... interactions with both PD-1 and B7.1 receptors. In this way, atezolizumab may enable the reactivation of T-cells, though it ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
and developability comparable to the commercial therapeutic antibody Atezolizumab. Additionally, antibodies designed for EGFR(S468R) displayed exceptional specificity, precisely distinguishing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback